Liver Failure Group, UCL Institute for Liver and Digestive Health, UCL Medical School, Royal Free Hospital, Rowland Hill Street, London,
United Kingdom; 2Liver Unit, Hospital Clnic, University of Barcelona, Barcelona, Catalunya, Spain, Institut dInvestigacions Biomdiques
August-Pi-Sunyer (IDIBAPS), Centro de Investigacin Biomdica en Red de Enfermedades Hepticas yDigestivas (CIBEREHED), Spain; 3Division of
Gastroenterology and Hepatology, Mayo Clinic, College of Medicine, Rochester, MN, United States; 4INSERM, U773, Centre de Recherche
Biomdicale Bichat-Beaujon CRB3, Paris and Clichy, France; 5Section of Digestive Diseases, Yale University School of Medicine,
New Haven, CT, United States
Summary
Acute-on-chronic liver failure (ACLF) is an increasingly recognised entity encompassing an acute deterioration of liver function
in patients with cirrhosis, which is usually associated with a
precipitating event and results in the failure of one or more
organs and high short term mortality. Prospective data to dene
this is lacking but there is a large body of circumstantial evidence
suggesting that this condition is a distinct clinical entity. From
the pathophysiologic perspective, altered host response to injury
and infection play important roles in its development. This
review focuses upon the current understanding of this syndrome
from the clinical, prognostic and pathophysiologic perspectives
and indicates potential biomarkers and therapeutic targets for
intervention.
2012 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.
Introduction
Epidemiology
Keywords: Acute-on chronic liver failure; Hepatorenal syndrome; Hepatic encephalopathy; Immune failure; Liver support; Liver transplantation.
Received 3 April 2012; received in revised form 19 June 2012; accepted 19 June 2012
Corresponding author. Address: Liver Failure Group, UCL Institute for Liver and
Digestive Health, UCL Medical School, Royal Free Hospital, Rowland Hill Street,
London NW3 2PF, United Kingdom. Tel.: +44 2074332795.
E-mail address: r.jalan@ucl.ac.uk (R. Jalan).
JOURNAL OF HEPATOLOGY
Table 1. SOFA scoring system.
Acute insult
100
Organ
Measurement
Score
400 mmHg
Platelet count
Months
Fig. 1. Acute-on chronic liver failure: diagrammatic representation of the
clinical concept. This gure describes the clinical concept of ACLF to distinguish
it from chronic decompensated cirrhosis. The red line describes the course of a
patient with chronic decompensation of cirrhosis that during evolution of their
liver disease will at some point develop organ dysfunction. This is usually in
association with advanced liver disease where the only option for treatment is
liver transplantation and the chances of reversibility of liver disease are very
limited. This is in contradistinction to the patient with acute-on chronic liver
failure (depicted by the blue line) who may often have a good liver reserve and
can deteriorate acutely over a short period, usually in association with a
precipitating illness that results in organ failure and high risk of death. The
patient may also have advanced liver disease but be stable and deteriorate
acutely following a precipitating event, and progress to organ failure. By contrast,
this patient has a potential for reversibility and recovery to the state the patient
was in, prior to the acute event.
that in patients with cirrhosis who present with acute deterioration of cirrhosis due to a precipitating factor and progress to
develop a single organ dysfunction have signicantly different
outcome to those that do not develop a single organ dysfunction
[4]. In a prospective study to explore this hypothesis, a group of
patients with liver cirrhosis that were admitted to a single unit
over a 5.5-year period and managed according pre-dened management guidelines were analyzed. Organ failure was dened as
the need for support of any organ. The patients were followed-up
clinically and biochemically until death or transplantation.
Among the approximately 500 patients studied, about one third
developed a single organ failure, of which 53% died during the
rst hospital admission, also indicating that the occurrence of a
single organ dysfunction was reversible in nearly 50% of cases.
The study also showed that both the severity of inammation
and the occurrence of new infection were associated with a
higher risk of death [5].
The prognostic factors determining the outcome of patients
with cirrhosis and multiorgan failure are currently under evaluation, but it seems that the scoring systems addressing the severity of liver disease, such as Child-Pugh score [6] or Model of End
Stage Liver Disease (MELD) [7] perform less well than the scoring
systems addressing organ dysfunction such as the Sequential
Organ Failure Assessment (SOFA) (Table 1) [8] or the Acute Physiology, Age and Chronic Health Evaluation (APACHE) [9] scores.
The available data describing the outcome of patients with cirrhosis who develop organ failure and are admitted to the ICU
are summarized in Table 2 and 3 [1044]. Critical examination
of the data indicates two fundamentally important conclusions.
First, the data suggest that the occurrence of an organ failure in
patients with cirrhosis with a dened severity of liver disease
indicates a poor prognosis with very wide survival gures, which
is possibly related to criteria for ICU admission. This notion is
supported by the second conclusion that it is not the severity of
Serum bilirubin
Hypotension
<100 mmHg
150,000 per l
<20,000 per l
<1.2 mg/dl
12.0 mg/dl
MAP 70 mmHg
Serum creatinine or
urine output
Dopamine 5 g/kg/min
4
0
13-14
10-12
6-9
3-5
liver disease measured using conventional clinical and biochemical testing (Child-Pugh score) that is important, but the degree of
end-organ failure that determines outcome. In these complex
patients, a concept similar to the PIRO concept in sepsis (predisposition, infection/inammation, response, organ failure) [45] might
be useful in describing pathophysiology and clinical categories
(Fig. 2).
1337
Review
Table 2. Comparison of the current literature on mortality rates of patients with cirrhosis and organ failure.
Reference
Number of patients
Patient selection
100
Cirrhosis on ICU, MV
89
100
Cirrhosis on ICU
64
198
Cirrhosis on ICU
117
Cirrhosis on ICU, MV
47
Cirrhosis on ICU, MV
83
54
Cirrhosis on ICU
43
138
Cirrhosis on ICU
56
582
Cirrhosis on ICU
37
49
143
Cirrhosis on ICU
36
46
111
Cirrhosis on ICU
65
76
68
67
87
Ho et al., 2003
135
Cirrhosis on ICU
67
160
Cirrhosis on ICU
63
420
Cirrhosis on ICU
129
Cirrhosis on ICU
74
76
Cirrhosis on ICU, MV
59
73
312
Cirrhosis on ICU
65
107
102
Cirrhosis on ICU
134
Cirrhosis on ICU
128
111
104
Cirrhosis on ICU
42
412
Cirrhosis on ICU
61
69 (1-yr mortality)
58
88
68
68
55
82
56
137
Cirrhosis on ICU
38
47
86
Cirrhosis on ICU
37
48
73
Cirrhosis on ICU, MV
75
88
377
Cirrhosis on ICU
35
43
441
Cirrhosis on ICU
660
Cirrhosis on ICU
51
Pathophysiological basis
Precipitating event (I)
ACLF usually results following a precipitating event on the background of established cirrhosis. The event may directly exaggerate liver injury such as alcoholic hepatitis, drug-induced liver
injury, superimposed viral hepatitis, portal vein thrombosis and
ischemic hepatitis or liver decompensation may be consequent
upon extra-hepatic insults such as trauma, surgery, variceal
bleeding or infection. In a proportion of patients, there may be
no identiable precipitating event. The best studied precipitating
events are surgery and superimposed viral hepatitis in relation to
the development of ACLF. The most important predictors of
post-operative mortality were severity of liver disease as
1338
JOURNAL OF HEPATOLOGY
Table 3. Comparison of data on prognostic accuracy of organ failure scores and liver disease scores in patients with liver cirrhosis and organ failure.
Reference
Zauner et al., 1996
Number of Patient
patients
selection
198
Cirrhosis on ICU
117
54
Cirrhosis on ICU,
MV
Cirrhosis on ICU
138
Cirrhosis on ICU
111
143
Cirrhosis on ICU,
bleeding
Cirrhosis on ICU
Ho et al., 2003
135
Cirrhosis on ICU
111
Cirrhosis on ICU
76
Cirrhosis on ICU,
bleeding
Cirrhosis on ICU
160
67
76
APACHE II
(AUROC)
0.75
APACHE III
(AUROC)
0.8
SOFA
OFS
Child-Pugh
(AUROC) (AUROC) score (AUROC)
-
Accurate for
risk stratification
Predicts
mortality
Predicts
mortality
0.78
Does not
predict mortality
0.76
0.79
0.94
0.74
0.833
0.75
0.901
0.887
0.900
0.892
0.66
420
Cirrhosis on ICU,
renal failure
Cirrhosis on ICU,
MV
Cirrhosis on ICU
0.878
312
Cirrhosis on ICU
0.78
102
Cirrhosis on ICU
134
128
111
104
Cirrhosis and
renal failure on ICU
Cirrhosis on ICU
after 48 h
Cirrhosis on ICU
with renal failure
Cirrhosis on ICU
412
Cirrhosis on ICU
137
86
73
377
441
Cirrhosis on ICU
Cirrhosis on ICU
Cirrhosis on ICU
requiring mechanical
ventilation
Cirrhosis on ICU
Cirrhosis on ICU
0.748
0.706
0.906
0.712
0.873
0.87
Predicts
mortality
0.72
0.83
0.91
0.91
0.92
0.78
0.88
0.90
0.93
0.85
0.78
0.84
0.77
0.94
0.83
0.92
0.79
more likely to suffer decompensation, which is common in carriers who receive immunosuppressive therapy [50,51]. In a study
from India, patients with reactivation of HBV and ACLF were
shown to have improved survival if they were treated with tenofovir compared with no therapy [52]. Although the ethics of this
study can be questioned, it illustrates that early intervention may
prevent occurrence of multiorgan failure by aggressively targeting the precipitating event. This principle is also illustrated by
the demonstration that survival of patients with variceal bleeding
can be improved by the prompt use of antibiotics, which reduces
the risk of infection [53]. Rapid control of the bleeding episode
with the insertion of a transjugular intrahepatic stent shunt in
patients with advanced liver disease or those with active
1339
Review
The PIRO concept of acute-on chronic liver failure
Assessment
Intervention
Predisposition
Severity of cirrhosis
Aetiology
Pugh score
MELD
[Biomarkers]
Early identification
Risk stratification
Preventative strategies
[Novel interventions]
Injury
Precipitating event
Hepatic
Extra-hepatic
[Therapies]
Response
Inflammation
Inflammation
Immune failure
[Biomarkers]
Vigilance, monitoring
Goal directed approaches
[Biomarkers and novel interventions]
Organ
Organ failure
SOFA
APACHE
[Biomarkers]
Fig. 2. The PIRO concept of acute-on chronic liver failure. In patients with ACLF, it is useful to think about the PIRO concept in determining pathogenesis and prognosis.
Predisposition is indicated by the severity of the underlying illness. Injury by the nature and severity of the precipitating event. Response by host response to injury, which
determines the severity of inammation and risk of infection. Organs by the extent of organ failure. Categorisation of patients into these entities allows denition of
interventions and helps dene prognosis at different levels.
in-dwelling cannulas and very early treatment remain the cornerstones of therapy. The relationship between the SIRS response
and infection leads one to hypothesise that an inammatory
response may lead to immune dysregulation, which may predispose to infection that would then further aggravate a pro-inammatory response resulting in a vicious cycle [56]. This
immunopathology of ACLF is reminiscent of the multimodal
immunological response observed in patients with severe sepsis,
which is characterised by an initial SIRS response followed by a
mixed (MARS) and subsequently compensated anti-inammatory
response (CARS) (Fig. 3 and 4).
The associated mechanisms of this phenomenon are not clear
but immune paresis has been suggested as a possible mechanism
[7173]. A recent study in cirrhotic patients suggested that a
genetic predisposition may underlie the risk of infection. The
investigators focussed on Toll-like receptor (TLR) 2 and nucleotide-binding oligomerisation domain (NOD) 2 which recognize
pathogen-associated molecular patterns (PAMS). In a multivariate analysis, they conrmed that TLR2 GT microsatellite polymorphism and NOD2 variants were independent predictors of
spontaneous bacterial peritonitis (SBP) when both risk factors
were present, the risk of SBP was dramatically increased (odds
ratio: 11.3; p = 0.00002) [74]. In alcoholic hepatitis patients,
neutrophil activation indicated by increased resting burst and
reduced phagocytic function was predictive of subsequent
JOURNAL OF HEPATOLOGY
SIRS: Systemic inflammatory response
Immune paralysis
Innate immunity
Neutrophils: phagocytic defect
Monocytes: DR loss
NK cells
Normal
ACLF: survivor
ACLF: non-survivor
Immune response
Endotoxemia
Reduced protein/complement synthesis
Reduced immune surveillance
Reduced albumin function
Adaptive immunity
T-cell exhaustion
Inability to profilerate
Increased apoptosis
Fig. 3. Immune dysfunction of acute-on chronic liver failure. This gure describes the level of immune dysfunction that may be operative in patients with acute-on
chronic liver failure and proposes the hypothesis that the immune status of patients during the illness may not be constant. Patients may move from a pro-inammatory to
an anti-inammatory state, making them susceptible to infection. It is likely that the patients that do not resolve the compensated anti-inammatory response are the ones
that will become infected and have the highest mortality rates.
Bacterial translocation
Bacterial infection
SIRS
Worsening systemic and
hepatic hemodynamics/
liver function
Compensated
cirrhosis
Increasing portal
pressure, fibrosis
and vasodilatation
Multiorgan failure
Decompensated
cirrhosis
Death
Hypotension
Renal failure
Jaundice
Coagulopathy
Encephalopathy
VH
Ascites
HE
Fig. 4. Role of bacterial translocation in acute-on chronic liver failure. In the transition from compensated to decompensated cirrhosis (marked by the development of
variceal hemorrhage, ascites and/or hepatic encephalopathy) increasing portal pressure and liver brosis play a predominant role, while vasodilatation (and the resultant
hyperdynamic circulatory state) is not as prominent. Conversely, the development of multiorgan failure is characterized by signicant alterations in systemic and hepatic
hemodynamics and worsening of liver function. Bacterial translocation plays an important role in the transition of patients from compensated to decompensated cirrhosis,
and together with bacterial infection is the most frequent precipitant of such deterioration via the systemic inammatory response. VH, variceal hemorrhage; HE, hepatic
encephalopathy.
1341
Review
infection, organ failure and mortality [72]. Importantly, data from
ex vivo studies showed that this neutrophil dysfunction was
reversible and possibly due to a circulating humoral factor that
was hypothesised to be endotoxin [72]. In another study,
monocyte HLA-DR expression was signicantly reduced in ACLF
who also showed an inability to produce TNF-a, the severity of
which correlated with survival [7173]. These observations
provide potential biomarkers to predict infection risk and allow
individualisation of therapy. Modulation of enteric microora
with probiotic therapy has been shown to restore neutrophil phagocytic capacity [75]. In a randomised clinical trial,
administration of the granulocyte-colony stimulating factor was
associated with improved survival of patients with ACLF [76].
The study included 47 patients with ACLF using the APASL denition and the investigators showed a very high 2-month mortality
of 71% in the untreated group compared with about 30% in the
treated group. Clearly, this study will need to be repeated with
larger numbers of patients but provides the proof of concept
that modulation of immune paresis may prevent the progression
of ACLF.
1342
JOURNAL OF HEPATOLOGY
with improved survival in patients with renal failure [100,101].
Administration of prophylactic noroxacin, a selective gut decontaminant reduced the incidence of renal failure and improved
survival [102]. The mechanism of the protective effect of noroxacin was explored in animal models of cirrhosis and AKI and
shown to result from modulation of renal NFkB and cytokines
possibly mediated through a TLR4-based mechanism. In a preliminary observation, increased TLR4 has been shown in renal
tubules in ACLF patients, which was not observed in HRS [103].
These data provide potential novel insights into pathophysiology
and the potential for the development of novel biomarkers and
therapeutic approaches. Thus, the use of urinary biomarkers that
reect renal injury may allow early diagnosis of renal dysfunction
of cirrhosis and allow the functional causes of renal dysfunction
to be better distinguished from the inammatory causes. The biomarkers of interest are markers of tubular injury such as kidney
injury molecule-1, pi and alpha glutathione S-transferase; markers of inammation such as NAG, NGAL, FABP, and IL-18 [104]. It
is possible that novel therapeutic approaches may be developed if
this hypothesis can be conrmed.
Inflammation
Hyperammonemia
Astrocytic swelling
Activation of NFkB
Cytokines
Oxidative stress
iNOS; nitrotyrosine
Brain dysfunction
Hepatic encephalopathy (HE) is a common manifestation of ACLF
[1,105107]. Local and systemic changes have been implicated in
the pathophysiology of the development of this neurological syndrome. From the pathophysiological perspective, like the situation in acute liver failure, brain swelling is an important feature
of ACLF also [105108]. As the syndrome occurs on the background of existing cirrhosis and chronic portacaval shunting, a
degree of brain atrophy protects from this brain swelling, resulting in an increase in intracranial pressure. There are, however,
several reports of signicant increases in intracranial pressure
in patients with ACLF [105107]. Studies using MRI have shown
that this increase in brain swelling can be reversed with liver
transplantation supporting the notion that, like acute liver failure, the brain manifestation of ACLF is a reversible disorder
[109]. Ammonia is thought to play a key role in the development
of HE but no direct relationship between the severity of hyperammonemia and HE could be demonstrated [110]. On the background of this hyperammonemia, an added hepatic insult and/
or superimposed inammation leads to the development of brain
edema suggesting a synergy between ammonia and inammation. The synergy between ammonia and inammation has been
demonstrated in animal models of cirrhosis where acute brain
swelling was observed following administration of endotoxin
mimicking the clinical situation seen in ACLF [108]. The mechanism is likely to be related to generation of cytokines in the brain,
increased iNOS expression, oxidative stress and formation of
nitrated protein adducts [108,111]. Studies in animal models
have suggested that ammonia may prime the brain to the deleterious effects of superimposed inammation by induction of
microglial cells, which have a huge repertoire for cytokine production; and a reduction in ammonia in cirrhotic models prevents the effect of superimposed inammation [108,111113].
Conversely, reduction in bacterial translocation using a nonabsorbable antibiotic, rifaximin was shown to prevent the occurrence of HE, suggesting that reducing inammation may be protective as well [114]. Cerebral blood ow is known to be
progressively reduced in cirrhosis but in ACLF may be paradoxically increased as seen in patients with acute liver failure. In a
Hepatic Encephalopathy
Fig. 5. Pathophysiological mechanisms of brain dysfunction in acute-on
chronic liver failure. This gure describes the possible mechanisms underlying
the pathogenesis of hepatic encephalopathy in acute-on chronic liver failure. It is
likely that similar mechanisms are operative in other organs, where susceptibility
to an inammatory insult is provided by organ characteristics that are a feature of
that particular organ in cirrhosis.
recent study, the acute effect of insertion of a transjugular intrahepatic shunt, which is known to induce endotoxemia, was studied in patients with cirrhosis. The study demonstrated that TIPSSinduced endotoxemia led to an increase in the rate of production
of nitric oxide, which was associated with endothelial dysfunction and increased cerebral blood ow supporting the hypothesis
that multiple hits and brain swelling is a feature of ACLF [115]
(Fig. 5). However, the insertion of TIPSS in relatively well cirrhotics without hepatic encephalopathy undergoing TIPSS was not
associated with a change in cerebral blood ow, stressing the
pathophysiologically distinct nature of ACLF from otherwise stable cirrhosis [116].
Cardiac and systemic hemodynamics
In patients with decompensated cirrhosis, a hyperdynamic circulation is the key hemodynamic feature. The increased cardiac
output observed in this situation is mainly due to a vasodilated
splanchnic bed but paradoxically, the blood ow in other
organ, such as kidneys, brain and peripheral organs, is
decreased [117]. Additionally, patients with cirrhosis may have
an underlying cirrhotic cardiomyopathy, which may make
them susceptible to cardiovascular collapse during an acute
inammatory insult, but data supporting that hypothesis does
not exist [118]. The hallmark of ACLF is cardiovascular collapse
akin to the patients with acute liver failure and severe sepsis,
often requiring large doses of inotropes. Unlike decompensated
cirrhosis, where the cardiac output remains elevated, in ACLF,
1343
Review
despite splanchnic vasodilation, the cardiac output can be
reduced and both systolic and diastolic functions are affected.
This cardiovascular abnormality is associated with increased
risk of death, particularly in those patients who present with
renal dysfunction [119]. In another study, where the denition
of ACLF was based upon the APASL criteria, no differences in
cardiac output were observed, highlighting the fact that the
designation is crucial in dening which patients are being
described. The mechanisms underlying the cardiac dysfunction
in ACLF are likely similar to those in severe sepsis, such as cardiovascular-active factors like TNF and nitric oxide which are
increased, and cortisol which is decreased [120]. The former
can further dilate the vasculature and the latter decreases the
sensitivity to vasoconstrictors. However, no study has yet demonstrated the benet of vasodilators/vasoconstrictors in the
management of ACLF. It is important to monitor the cardiac
situation using appropriate methods to guide uid replacement
and inotrope support. The choice of inotropes is also unclear
but vasopressin analogue in this situation should be used cautiously as it may further reduce cardiac perfusion and an
already compromised hepatic blood ow [121].
Coagulation
Routine diagnostic tests of coagulation are usually abnormal
in patients with cirrhosis due to multiple defects. An
increased bleeding tendency has been attributed to the degree
of abnormalities in these tests, but this has not been formally
proven [122]. Thrombin generation is normal in stable cirrhotics with a rebalancing of pro- and anti-coagulant factors (providing there are sufcient platelets >50,000 109/L). Since
hypercoagulation may exist [123], bleeding abnormalities are
far less frequent than it would be expected [124]. In cirrhosis
with sepsis, endogenous low-molecular weight heparinoids are
detected, and disappear with resolution of infection [68]. Antibiotics are known to reduce early variceal rebleeding rates
[125]. The use of prophylactic blood products to correct
abnormalities to prevent bleeding is empirical and often
guided by local protocols; virtually none of these are evidence-based [126]. Moreover, normalization of abnormal coagulation parameters is difcult to achieve, and creates volume
excess, increasing the risk of transfusion-related acute lung
injury and other transfusion reactions. Even recombinant factor VIIa, which corrects prothrombin time, does not reduce
blood loss during variceal bleeding [127]. Conversely, antibrinolytic agents do reduce blood loss during liver transplantation, but have not been evaluated prophylactically during
other procedures or for bleeding. Apart from increased brinolysis, which is seen in ACLF, defective platelet function is the
other major abnormality [128]. The thrombopoietin analog
eltrombopag may be thrombogenic at least in stable cirrhosis
(there has been a suspended trial in this area), probably
because of the interaction with the very high levels of vWF
in cirrhosis. The use of fresh frozen plasma is limited by the
volume of transfusions; safer prothrombin complex concentrates which have 20 times the concentration of factors than
FFP are now available [129]. Currently, prophylactic transfusions of any coagulation products are difcult to justify and
it is likely that more comprehensive, global tests of coagulation are needed to guide the correction of coagulation on an
individual basis [130].
1344
Hepato-adrenal axis
Adrenal insufciency is reported in 5168% of patients with
cirrhosis and severe sepsis, particularly in patients with high
Child-Pugh and MELD scores and hemodynamic instability.
Adrenal insufciency is associated with increased mortality
compared to patients without adrenal insufciency [131].
Administration of hydrocortisone to patients with septic shock
and adrenal insufciency was shown to improve the circulatory
function but routine use of hydrocortisone during sepsis has
not been conrmed to improve the outcome [132]. Interpretation of response to synacthen test in cirrhosis and ACLF is difcult due to methodological constraints, so no conclusions can
be made.
JOURNAL OF HEPATOLOGY
the RELIEF trial, which has been reported in a preliminary communication and again failed to show any survival benet [138].
A better denition of ACLF would allow the study of a more
homogenous cohort, but it is likely that modications to the
current devices will be necessary to improve their efcacy and
capacity.
Liver transplantation in patients with ACLF has not been systematically analysed but a recent retrospective study was performed in 332 patients of whom 157 patients had ACLF and
175 patients had no ACLF pre-transplant [139]. Thirty-four
patients received a liver-kidney transplant, of whom 10
(29.4%) had ACLF. The denition was based on a rapid increase
in MELD by >5 points. The results showed that the group with
ACLF had a 26% mortality compared with a mortality of 17% in
the non-ACLF group. The difference was statistically different in
univariate analysis, but when only single organ transplants
were analysed, the results were not statistically different. On
multivariate analysis, ACLF was not an independent predictor
of post-transplant mortality, arguing strongly that this is a
good indication for transplantation [139]. The timing of transplantation is crucial as patients with ACLF may provide a window of opportunity. Therefore, living-donor transplantation is
an attractive option, the experience of which has been reported
extensively from South-East Asia, mainly in patients with ACLF
resulting from re-activation of hepatitis B virus infection. The
data from Hong Kong suggests that although the patients with
ACLF and HRS had stormier post-operative course, living donor
transplantation could be performed safely and overall there
were no signicant differences in survival with 5-year survivals
of about 80% [140]. Similar observations have been made
regarding the safety and feasibility of living donor transplantation from the Chinese groups [141]. Currently, in most countries there is no priority for ACLF patients who have
signicantly higher short-term mortality. A better understanding of the natural history and prognostic criteria will allow
ACLF to be incorporated as a possible new indication for high
urgency allocation.
Key Points
Conict of interest
The authors declared that they do not have anything to disclose
regarding funding or conict of interest with respect to this
manuscript.
Acknowledgements
1345
Review
[6] Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection
of the oesophagus for bleeding oesophageal varices. Br J Surg
1973;60:646649.
[7] Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg
CL, et al. A model to predict survival in patients with end-stage liver
disease. Hepatology 2001;33:464470.
[8] Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al.
The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ
dysfunction/failure. On behalf of the Working Group on Sepsis-Related
Problems of the European Society of Intensive Care Medicine. Intensive
Care Med 1996;22:707710.
[9] Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of
disease classication system. Crit Care Med 1985;13:818829.
[10] Goldfarb G, Nouel O, Poynard T, Rueff B. Efciency of respiratory assistance
in cirrhotic patients with liver failure. Intensive Care Med 1983;9:271273.
[11] Shellman RG, Fulkerson WJ, DeLong E, Piantadosi CA. Prognosis of patients
with cirrhosis and chronic liver disease admitted to the medical intensive
care unit. Crit Care Med 1988;16:671678.
[12] Zauner CA, Apsner RC, Kranz A, Kramer L, Madl C, Schneider B, et al.
Outcome prediction for patients with cirrhosis of the liver in a medical ICU:
a comparison of the APACHE scores and liver-specic scoringsystems.
Intensive Care Med 1996;22:559563.
[13] Zimmerman JE, Wagner DP, Seneff MG, Becker RB, Sun X, Knaus WA.
Intensive care unit admissions with cirrhosis: risk-stratifying patient
groups and predicting individual survival. Hepatology 1996;23:13931401.
[14] Lee KC, Chiang AA. The outcome of terminal liver cirrhosis patients
requiring mechanical ventilation. Zhonghua Yi Xue Za Zhi (Taipei)
1997;59:8894.
[15] Singh N, Gayowski T, Wagener MM, Marino IR. Outcome of patients with
cirrhosis requiring intensive care unit support: prospective assessment of
predictors of mortality. J Gastroenterol 1998;33:7379.
[16] Kress JP, Rubin A, Pohlman AS, Hall JB. Outcomes of critically ill patients
denied consideration for liver transplantation. Am J Respir Crit Care Med
2000;162:418423.
[17] Aggarwal A, Ong JP, Younossi ZM, Nelson DR, Hoffman-Hogg L, Arroliga AC.
Predictors of mortality and resource utilization in cirrhotic patients
admitted to the medical ICU. Chest 2001;119:14891497.
[18] Wehler M, Kokoska J, Reulbach U, Hahn EG, Strauss R. Short-term prognosis
in critically ill patients with cirrhosis assessed by prognostic scoring
systems. Hepatology 2001;34:255261.
[19] Tsai MH, Chen YC, Ho YP, Fang JT, Lien JM, Chiu CT, et al. Organ system
failure scoring system can predict hospital mortality in critically ill cirrhotic
patients. J Clin Gastroenterol 2003;37:251257.
[20] Tsai MH, Peng YS, Lien JM, Weng HH, Ho YP, Yang C, et al. Multiple organ
system failure in critically ill cirrhotic patients. A comparison of two
multiple organ dysfunction/failure scoring systems. Digestion 2004;69:
190200.
[21] Chen YC, Tsai MH, Ho YP, Hsu CW, Lin HH, Fang JT, et al. Comparison of the
severity of illness scoring systems for critically ill cirrhotic patients with
renal failure. Clin Nephrol 2004;61:111118.
[22] Chen YC, Tsai MH, Hsu CW, Ho YP, Lien JM, Chang MY, et al. Role of serum
creatinine and prognostic scoring systems in assessing hospital mortality in
critically ill cirrhotic patients with upper gastrointestinal bleeding. J
Nephrol 2003;16:558565.
[23] Ho YP, Chen YC, Yang C, Lien JM, Chu YY, Fang JT, et al. Outcome prediction
for critically ill cirrhotic patients: a comparison of APACHE II and ChildPugh scoring systems. J Intensive Care Med 2004;19:105110.
[24] Gildea TR, Cook WC, Nelson DR, Aggarwal A, Carey W, Younossi ZM, et al.
Predictors of long-term mortality in patients with cirrhosis of the liver
admitted to a medical ICU. Chest 2004;126:15981603.
[25] Cholongitas E, Senzolo M, Patch D, Kwong K, Nikolopoulou V, Leandro G,
et al. Risk factors, sequential organ failure assessment and model for endstage liver disease scores for predicting short term mortality in cirrhotic
patients admitted to intensive care unit. Aliment Pharmacol Ther
2006;23:883893.
[26] Afessa B, Kubilis PS. Upper gastrointestinal bleeding in patients with
hepatic cirrhosis: clinical course and mortality prediction. Am J Gastroenterol 2000;95:484489.
[27] Rabe C, Schmitz V, Paashaus M, Musch A, Zickermann H, Dumoulin FL, et al.
Does intubation really equal death in cirrhotic patients? Factors inuencing
outcome in patients with liver cirrhosis requiring mechanical ventilation.
Intensive Care Med 2004;30:15641571.
[28] du Cheyron D, Bouchet B, Parienti JJ, Ramakers M, Charbonneau P. The
attributable mortality of acute renal failure in critically ill patients with
liver cirrhosis. Intensive Care Med 2005;31:16931699.
1346
[29] Knaus WA, Wagner DP, Draper EA, Zimmerman JE, Bergner M, Bastos PG,
et al. The APACHE III prognostic system. Risk prediction of hospital
mortality for critically ill hospitalized adults. Chest 1991;100:16191636.
[30] Arabi Y, Ahmed QA, Haddad S, Aljumah A, Al-Shimemeri A. Outcome
predictors of cirrhosis patients admitted to the intensive care unit. Eur J
Gastroenterol Hepatol 2004;16:333339.
[31] Mackle IJ, Swann DG, Cook B. One year outcome of intensive care patients
with decompensated alcoholic liver disease. Br J Anaesth 2006;97:
496498.
[32] Chen YC, Tian YC, Liu NJ, Ho YP, Yang C, Chu YY, et al. Prospective cohort
study comparing sequential organ failure assessment and acute physiology,
age, chronic health evaluation III scoring systems for hospital mortality
prediction in critically ill cirrhotic patients. Int J Clin Pract
2006;60:160166.
[33] Jenq CC, Tsai MH, Tian YC, Lin CY, Yang C, Liu NJ, et al. RIFLE classication
can predict short-term prognosis in critically ill cirrhotic patients. Intensive
Care Med 2007;33:19211930.
[34] Cholongitas E, Betrosian A, Senzolo M, Shaw S, Patch D, Manousou P, et al.
Prognostic models in cirrhotics admitted to intensive care units better
predict outcome when assessed at 48 h after admission. Gastroenterol
Hepatol 2008;23:12231227.
[35] Fang JT, Tsai MH, Tian YC, Jenq CC, Lin CY, Chen YC, et al. Outcome
predictors and new score of critically ill cirrhotic patients with acute renal
failure. Nephrol Dial Transplant 2008;23:19611969.
[36] Juneja D, Gopal PB, Kapoor D, Raya R, Sathyanarayanan M, Malhotra P.
Outcome of patients with liver cirrhosis admitted to a specialty liver
intensive care unit in India. J Crit Care 2009;24:387393.
[37] Cholongitas E, Calvaruso V, Senzolo M, Patch D, Shaw S, OBeirne J, et al.
RIFLE classication as predictive factor of mortality in patients with
cirrhosis admitted to intensive care unit. J Gastroenterol Hepatol
2009;24:16391647.
[38] Thomson SJ, Moran C, Cowan ML, Musa S, Beale R, Treacher D, et al.
Outcomes of critically ill patients with cirrhosis admitted to intensive care:
an important perspective from the non-transplant setting. Aliment Pharmacol Ther 2010;32:233243.
[39] Filloux B, Chagneau-Derrode C, Ragot S, Voultoury J, Beauchant M, Silvain C,
et al. Short-term and long-term vital outcomes of cirrhotic patients
admitted to an intensive care unit. Eur J Gastroenterol Hepatol
2010;22:14741480.
[40] Juneja D, Gopal PB, Kapoor D, Raya R, Sathyanarayanan M. Proles and
outcome of patients with liver cirrhosis requiring mechanical ventilation. J
Intensive Care Med (in press).
[41] Feltracco P, Brezzi M, Barbieri S, Milevoj M, Galligioni H, Cillo U, et al.
Intensive care unit admission of decompensated cirrhotic patients: prognostic scoring systems. Transplant Proc 2011;43:10791084.
[42] Levesque E, Hoti E, Azoulay D, Icha P, Habouchi H, Castaing D, et al.
Prospective evaluation of the prognostic scores for cirrhotic patients
admitted to an intensive care unit. J Hepatol 2012;56:95102.
[43] Cavallazzi R, Awe OO, Vasu TS, Hirani A, Vaid U, Leiby BE, et al. Model for
End-stage liver disease score for predicting outcome in critically ill medical
patients with liver cirrhosis. J Crit Care 2012;27:424.e1424.e6.
[44] Shawcross DL, Austin MJ, Abeles RD, McPhail MJ, Yeoman AD, Taylor NJ,
et al. The impact of organ dysfunction in cirrhosis: survival at a cost? J
Hepatol 2012;56:10541062.
[45] Moreno RP, Metnitz B, Adler L, Hoechtl A, Bauer P, Metnitz PG. SAPS 3
Investigators. Sepsis mortality prediction based on predisposition, infection
and response. Intensive Care Med 2008;34:496504.
[46] Plataki M, Hubmayr RD. The physical basis of ventilator-induced lung
injury. Expert Rev Respir Med 2010;4:373385.
[47] Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, et al.
Risk factors for mortality after surgery in patients with cirrhosis. Gastroenterology 2007;132:12611269.
[48] Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis
B and other chronic liver diseases? Am J Gastroenterol 1995;90:
201205.
[49] Kumar Acharya S, Kumar Sharma P, Singh R, Kumar Mohanty S, Madan K,
Kumar Jha J, et al. Hepatitis E virus (HEV) infection in patients with
cirrhosis is associated with rapid decompensation and death. J Hepatol
2007;46:387394.
[50] Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al.
Systematic review: the effect of preventive lamivudine on hepatitis B
reactivation during chemotherapy. Ann Intern Med 2008;148:519528.
[51] Carman WF, Korula J, Wallace L, MacPhee R, Mimms L, Decker R. Fulminant
reactivation of hepatitis B due to envelope protein mutant that escaped
detection by monoclonal HBsAg ELISA. Lancet 1995;345:14061407.
JOURNAL OF HEPATOLOGY
[52] Garg H, Sarin SK, Kumar M, Garg V, Sharma BC, Kumar A. Tenofovir improves
the outcome in patients with spontaneous reactivation of hepatitis B
presenting as acute-on-chronic liver failure. Hepatology 2011;53:774780.
[53] Bernard B, Grange JD, Khac EN, Amiot X, Opolon P, Poynard T. Antibiotic
prophylaxis for the prevention of bacterial infections in cirrhotic patients
with gastrointestinal bleeding: a meta-analysis. Hepatology 1999;29:
16551661.
[54] Monescillo A, Martnez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C,
Jimnez E, et al. Inuence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology
2004;40:793801.
[55] Garca-Pagn JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al.
Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative
Study Group. Early use of TIPS in patients with cirrhosis and variceal
bleeding. N Engl J Med 2010;362:23702379.
[56] Malik R, Mookerjee RP, Jalan R. Infection and inammation in liver failure:
two sides of the same coin. J Hepatol 2009;51:426429.
[57] Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R.
The systemic inammatory response syndrome in acute liver failure.
Hepatology 2000;32:734739.
[58] Vaquero J, Polson J, Chung C, Helenowski I, Schiodt FV, Reisch J, et al.
Infection and the progression of hepatic encephalopathy in acute liver
failure. Gastroenterology 2003;125:755764.
[59] Jalan R, Olde Damink SW, Hayes PC, Deutz NE, Lee A, et al. Pathogenesis of
intracranial hypertension in acute liver failure: inammation, ammonia
and cerebral blood ow. J Hepatol 2004;41:613620.
[60] Gustot T. Multiple organ failure in sepsis: prognosis and role of systemic
inammatory response. Curr Opin Crit Care 2011;17:153159.
[61] Sen S, Davies NA, Mookerjee RP, Cheshire LM, Hodges SJ, Williams R, et al.
Pathophysiological effects of albumin dialysis in acute-on-chronic liver
failure: a randomized controlled study. Liver Transpl 2004;10:11091119.
[62] Cazzaniga M, Dionigi E, Gobbo G, Fioretti A, Monti V, Salerno F. The
systemic inammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. J Hepatol 2009;51:475482.
[63] Thabut D, Massard J, Gangloff A, Carbonell N, Francoz C, Nguyen-Khac E,
et al. Model for end-stage liver disease score and systemic inammatory
response are major prognostic factors in patients with cirrhosis and acute
functional renal failure. Hepatology 2007;46:18721882.
[64] Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, Piquet MA,
et al. Foie-alcool group of the association Franaise pour lEtude du Foie. A
double-blind randomized controlled trial of iniximab associated with
prednisolone in acute alcoholic hepatitis. Hepatology 2004;39:13901397.
[65] Boetticher NC, Peine CJ, Kwo P, Abrams GA, Patel T, Aqel B, et al. A
randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology
2008;135:19531960.
[66] Linderoth G, Jepsen P, Schonheyder HC, et al. Short-term prognosis of
community-acquired bacteremia in patients with liver cirrhosis or alcoholism: a population-based cohort study. Alcohol Clin Exp Res 2006;30:
636641.
[67] Borzio M, Salerno F, Piantoni L, et al. Bacterial infection in patients with
advanced cirrhosis: a multicentre prospective study. Dig Liver Dis
2001;33:4148.
[68] Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK.
Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a
prospective study. J Hepatol 2002;37:463470.
[69] Arvaniti V, DAmico G, Fede G, Manousou P, Tsochatzis E, Pleguezuelo M,
et al. Infections in patients with cirrhosis increase mortality four-fold and
should be used in determining prognosis. Gastroenterology 2010;139:
12461256.
[70] Gustot T, Durand F, Lebrec D, Vincent JL, Moreau R. Severe sepsis in
cirrhosis. Hepatology 2009;50:20222033.
[71] Wasmuth HE, Kunz D, Yagmur E, et al. Patients with acute on chronic liver
failure display sepsis-like immune paralysis. J Hepatol 2005;42:195201.
[72] Mookerjee RP, Stadlbauer V, Lidder S, Wright GA, Hodges SJ, Davies NA,
et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on
cirrhosis is reversible and predicts outcome. Hepatology 2007;46:831840.
[73] Berry PA, Antoniades CG, Carey I, McPhail MJ, Hussain MJ, Davies ET, et al.
Severity of the compensatory anti-inammatory response determined by
monocyte HLA-DR expression may assist outcome prediction in cirrhosis.
Intensive Care Med 2011;37:453460.
[74] Nischalke HD, Berger C, Aldenhoff K, Thyssen L, Gentemann M, Grnhage F,
et al. Toll-like receptor (TLR) 2 promoter and intron 2 polymorphisms are
associated with increased risk for spontaneous bacterial peritonitis in liver
cirrhosis. J Hepatol 2011;55:10101016.
[75] Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect
of probiotic treatment on deranged neutrophil function and cytokine
responses in patients with compensated alcoholic cirrhosis. J Hepatol
2008;48:945951.
[76] Garg V, Garg H, Khan A, Trehanpati N, Kumar A, Sharma BC, et al.
Granulocyte colony-stimulating factor mobilizes CD34(+) cells and
improves survival of patients with acute-on-chronic liver failure. Gastroenterology 2012;142:505512.
[77] Katoonizadeh A, Laleman W, Verslype C, Wilmer A, Maleux G, Roskams T,
et al. Early features of acute-on-chronic alcoholic liver failure: a prospective
cohort study. Gut 2010;59:15611569.
[78] Jalan R, Mookerjee RP. Acute-on-chronic liver failure: an early biopsy is
essential? Gut 2010;59:14551456.
[79] Mookerjee RP, Lackner C, Stauber R, Stadlbauer V, Deheragoda M, Aigelsreiter A, et al. The role of liver biopsy in the diagnosis and prognosis of
patients with acute deterioration of alcoholic cirrhosis. J Hepatol
2011;55:11031111.
[80] Adebayo D, Mookerjee RP, Jalan R. Mechanistic biomarkers in acute liver
injury: are we there yet? J Hepatol 2012;56:10031005.
[81] Mookerjee RP, Sen S, Davies NA, Hodges SJ, Williams R, Jalan R. Tumour
necrosis factor a is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 2003;52:11821187.
[82] Benten D, Wiest R. Gut microbiome and intestinal barrier failure The
Achilles heel in hepatology? J Hepatol 2012;56:12211223.
[83] Vlachogiannakos J, Saveriadis AS, Viazis N, Theodoropoulos I, Foudoulis K,
Manolakopoulos S, et al. Intestinal decontamination improves liver
haemodynamics in patients with alcohol-related decompensated cirrhosis.
Aliment Pharmacol Ther 2009;29:992999.
[84] Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of
selective intestinal decontamination on the hyperdynamic circulatory state
in cirrhosis. A randomized trial. Ann Intern Med 2003;139:186193.
[85] Thabut D, Tazi KA, Bonnefont-Rousselot D, Aller M, Farges O, Guimont MC,
et al. High-density lipoprotein administration attenuates liver proinammatory response, restores liver endothelial nitric oxide synthase activity, and
lowers portal pressure in cirrhotic rats. Hepatology 2007;46:18931906.
[86] Lavia B, Gracia-Sancho J, Rodrguez-Vilarrupla A, Chu Y, Heistad DD, Bosch
J, et al. Superoxide dismutase gene transfer reduces portal pressure in CCl4
cirrhotic rats with portal hypertension. Gut 2009;58:118125.
[87] Kumar A, Das K, Sharma P, Mehta V, Sharma BC, Sarin SK. Hemodynamic
studies in acute-on-chronic liver failure. Dig Dis Sci 2009;54:869878.
[88] Jalan R, Mookerjee RP. Systemic hemodynamics, hepatic blood ow and
portal pressure in patients with cirrhosis and multiorgan failure: the role of
sympathetic activation. Hepatology 2008;48 (Suppl. 1):1077A.
[89] Mookerjee RP, Wiesenthal A, Icking A, Hodges SJ, Davies NA, Schilling K,
et al. Increased gene and protein expression of the novel eNOS regulatory
protein NOSTRIN and a variant in alcoholic hepatitis. Gastroenterology
2007;132:25332541.
[90] Shah V, Haddad FG, Garcia-Cardena G, Frangos JA, Mennone A, Groszmann
RJ, et al. Liver sinusoidal endothelial cells are responsible for nitric oxide
modulation of resistance in the hepatic sinusoids. J Clin Invest
1997;100:29232930.
[91] Mookerjee RP, Malaki M, Davies NA, Hodges SJ, Dalton RN, Turner C, et al.
Increasing dimethylarginine levels are associated with adverse clinical
outcome in severe alcoholic hepatitis. Hepatology 2007;45:6271.
[92] Lee KC, Yang YY, Wang YW, Hou MC, Lee FY, Lin HC, et al. Acute
administration of sildenal enhances hepatic cyclic guanosine monophosphate production and reduces hepatic sinusoid resistance in cirrhotic
patients. Hepatol Res 2008;38:11861193.
[93] Gines P, Schrier RW. Renal failure in cirrhosis. N Engl J Med
2009;361:12791290.
[94] Martn-Llah M, Guevara M, Torre A, Fagundes C, Restuccia T, Gilabert R,
et al. Prognostic importance of the cause of renal failure in patients with
cirrhosis. Gastroenterology 2011;140:488496.
[95] Stadlbauer V, Wright G, Banaji M, Mukhopadhyay A, Mookerjee R, Moore K,
et al. Relationship between activation of the sympathetic nervous system
and renal blood ow autoregulation in cirrhosis. Gastroenterology
2008;134:111119.
[96] Nazar A, Pereira GH, Guevara M, Martn-Llahi M, Pepin MN, Marinelli M,
et al. Predictors of response to therapy with terlipressin and albumin in
patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology
2010;51:219226.
[97] Nadim MK, Genyk YS, Tokin C, Fieber J, Ananthapanyasut W, Ye W, et al.
Impact of etiology of acute kidney injury on outcomes following liver
transplantation: acute tubular necrosis versus hepatorenal syndrome. Liver
Transpl 2012;18:539548.
1347
Review
[98] Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, et al.
Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999;353:294295.
[99] Akriviadis E, Bolta R, Briggs W, et al. Pentoxifylline improves short-term
survival in severe alcoholic hepatitis: a double-blind, placebo-controlled
trial. Gastroenterology 2000;119:16371648.
[100] Sort P, Navasa M, Arroyo V, Aldeguer X, Planas R, Ruiz-del-Arbol L, et al.
Effect of intravenous albumin on renal impairment and mortality in
patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med
1999;5 (341):403409.
[101] Ortega R, Gins P, Uriz J, Crdenas A, Calahorra B, De Las Heras D, et al.
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002;36:941948.
[102] Fernndez J, Navasa M, Planas R, et al. Primary prophylaxis of spontaneous
bacterial peritonitis delays hepatorenal syndrome and improves survival in
cirrhosis. Gastroenterology 2007;133:818824.
[103] Shah N, Dhar D. El Zahraa Mohammed F, Habtesion A, Davies NA, JoverCobos M, et al. Prevention of acute kidney injury in a rodent model of
cirrhosis following selective gut decontamination is associated with
reduced renal TLR4 expression. J Hepatol 2012;56:10471053.
[104] Crdenas A, Gins P. Acute-on-chronic liver failure: the kidneys. Curr Opin
Crit Care 2011;17:184189.
[105] Crippin JS, Gross Jr JB, Lindor KD. Increased intracranial pressure and
hepatic encephalopathy in chronic liver disease. Am J Gastroenterol
1992;87:879882.
[106] Jalan R, Dabos K, Redhead DN, Lee A, Hayes PC. Elevation of intracranial
pressure following transjugular intrahepatic portosystemic stent-shunt for
variceal haemorrhage. J Hepatol 1997;27:928933.
[107] Donovan JP, Schafer DF, Shaw Jr BW, Sorrell MF. Cerebral edema and
increased intracranial pressure in chronic liver disease. Lancet
1998;351:719721.
[108] Wright G, Davies NA, Shawcross DL, Hodges SJ, Zwingmann C, Brooks HF,
et al. Endotoxemia produces coma and brain swelling in bile duct ligated
rats. Hepatology 2007;45:15171526.
[109] Garca Martnez R, Rovira A, Alonso J, Aymerich FX, Huerga E, Jacas C, et al.
A long-term study of changes in the volume of brain ventricles and white
matter lesions after successful liver transplantation. Transplantation
2010;89:589594.
[110] Shawcross DL, Shari Y, Canavan JB, Yeoman AD, Abeles RD, Taylor NJ, et al.
Infection and systemic inammation, not ammonia, are associated with
grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis. J Hepatol
2011;54:640649.
[111] Pedersen HR, Ring-Larsen H, Olsen NV, Larsen FS. Hyperammonemia acts
synergistically with lipopolysaccharide in inducing changes in cerebral
hemodynamics in rats anaesthetised with pentobarbital. J Hepatol
2007;47:245252.
[112] Rodrigo R, Cauli O, Gomez-Pinedo U, Agusti A, Hernandez-Rabaza V, GarciaVerdugo JM, et al. Hyperammonemia induces neuroinammation that
contributes to cognitive impairment in rats with hepatic encephalopathy.
Gastroenterology 2010;139:675684.
[113] Wright G, Vairappan B, Stadlbauer V, Mookerjee RP, Davies NA, Jalan R.
Reduction in hyperammonaemia by ornithine phenylacetate prevents
lipopolysaccharide-induced brain edema and coma in cirrhotic rats. Liver
Int 2012;32:410419.
[114] Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, et al. Rifaximin
treatment in hepatic encephalopathy. N Engl J Med 2010;25
(362):10711081.
[115] Jalan R, Olde Damink SW, Ter Steege JC, Redhead DN, Lee A, Hayes PC, et al.
Acute endotoxemia following transjugular intrahepatic stent-shunt insertion is associated with systemic and cerebral vasodilatation with increased
whole body nitric oxide production in critically ill cirrhotic patients. J
Hepatol 2011;54:265271.
[116] Iversen P, Keiding S, Mouridsen K, Ott P, Vilstrup H. Transjugular
intrahepatic portosystemic shunt does not alter cerebral blood ow. Clin
Gastroenterol Hepatol 2011;9:10011003.
[117] Helmy A, Jalan R, Newby DE, Hayes PC, Webb DJ. Role of angiotensin II in
regulation of basal and sympathetically stimulated vascular tone in early
and advanced cirrhosis. Gastroenterology 2000;118:565572.
[118] Liu H, Lee SS. Acute-on-chronic liver failure: the heart and systemic
hemodynamics. Curr Opin Crit Care 2011;17:190194.
[119] Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gins P, Moreira V, et al.
Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology
2005;42:439447.
1348